Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki 216-8511, Japan.
FEBS Lett. 2011 Sep 16;585(18):2836-44. doi: 10.1016/j.febslet.2011.05.005. Epub 2011 May 9.
Impairment of homologous recombination (HR), a vital process employed during repair of DNA double strand breaks and stalled DNA replication, provides a valuable opportunity for the cell to become transformed. Once transformed, the impairment turns to be a target for therapy as exemplified by the synthetic lethal strategy such as poly (ADP-ribose) polymerase (PARP) inhibitor for BRCA1/2-defective breast and ovarian cancer. Hence, improving mechanistic understanding of HR has emerged as an urgent issue to address due to the high clinical demand. Ubiquitin modification plays a central role in HR and more than a few E3 ubiquitin ligases have been implicated in the process. However, the significance of the activity of one such key E3 ligase, BRCA1, has not yet been clarified and remains as a major obstacle in the field. Here, we review recent advances in our understanding of BRCA1 function in HR and discuss possible roles of the activity.
同源重组(HR)的损伤,这是在修复 DNA 双链断裂和停滞的 DNA 复制过程中使用的一个重要过程,为细胞转化提供了一个有价值的机会。一旦转化,损伤就成为治疗的靶点,例如聚(ADP-核糖)聚合酶(PARP)抑制剂针对 BRCA1/2 缺陷型乳腺癌和卵巢癌的合成致死策略。因此,由于临床需求很高,提高对 HR 的机制理解已成为一个紧迫的问题。泛素修饰在 HR 中起着核心作用,并且已经有几种 E3 泛素连接酶参与了该过程。然而,一个关键的 E3 连接酶 BRCA1 的活性的意义尚未阐明,并且仍然是该领域的主要障碍。在这里,我们回顾了我们对 BRCA1 在 HR 中的功能的理解的最新进展,并讨论了其活性的可能作用。